Roducitabine is a small molecule commercialized by Processa Pharmaceuticals, with a leading Phase II program in Metastatic Pancreatic Cancer. According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Roducitabine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Roducitabine is expected to reach an annual total of $15 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Roducitabine is under development for the treatment of solid tumors such as refractory metastatic pancreatic cancer (third-line therapy), biliary cancer and non-small cell lung cancer. The drug candidate is administered through oral route. The drug candidate is a cytidine analog. It is a small molecule (fluorocyclopentenylcytosine), a prodrug, next-generation nucleoside compound. It acts by targeting DNA, RNA, and DNA methyltransferase 1. It was also under development for colorectal cancer, muscle-invasive bladder cancer (MIBC), small cell lung cancer, colon cancer, relapsed and renal cell carcinoma, ovarian cancer, advanced malignancies, metastatic bladder cancer resistant to gemcitabine and cervical cancer.
Processa Pharmaceuticals Overview
Processa Pharmaceuticals, formerly Heatwurx, is a biopharmaceutical company which develops and commercializes drugs for the treatment of skin diseases and various cancer types. It is investigating its lead product candidate: PCS499 to treat necrobiosis lipoidica (NL), a chronic, disfiguring skin disorder; and to treat the side effects of radiation in patients with head and neck cancer. The PCS499 holds Orphan Drug designation for the treatment of NL. The company is evaluating PCS100, an anti-fibrotic and anti-inflammatory drug against idiopathic pulmonary fibrosis (IPF) and primary glomerulonephritis. It operates in the US. Processa Pharmaceuticals is headquartered in Baltimore, Maryland, the US.
The operating loss of the company was US$12 million in FY2021, compared to an operating loss of US$15.1 million in FY2020. The net loss of the company was US$11.4 million in FY2021, compared to a net loss of US$14.4 million in FY2020.
For a complete picture of Roducitabine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.